BioRestorative Therapies, Inc. (FRA:9OF)
Germany · Delayed Price · Currency is EUR | Market Cap | 4.74M -54.0% |
| Revenue (ttm) | 310.38K -8.5% |
| Net Income | -9.59M |
| EPS | -0.85 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.1820 |
| Previous Close | 0.1860 |
| Day's Range | 0.1820 - 0.1820 |
| 52-Week Range | 0.1290 - 1.6600 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About BioRestorative Therapies
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to ... [Read more]
Financial Performance
In 2025, BioRestorative Therapies's revenue was $359,700, a decrease of -10.30% compared to the previous year's $401,000. Losses were -$14.24 million, 58.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
BioRestorative Therapies completes manufacturing for BRTX-100
BioRestorative Therapies (BRTX) announced the completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and und...
BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform
MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focuse...
BioRestorative Therapies Slides: Corporate presentation
BioRestorative Therapies has posted slides in relation to its latest quarterly earnings report, which was published on June 25, 2026.
BioRestorative Therapies appoints Smith as VP of Biocosmeceuticals Division
BioRestorative Therapies (BRTX) announced the appointment of Zachary Smith as Vice President, VP, of its Biocosmeceuticals Division, further strengthening the Company’s commercial leadership team as i...
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth
Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,”...
BioRestorative Therapies Slides: Corporate presentation
BioRestorative Therapies has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
BioRestorative Therapies shareholder Kaos Capital acquires 4.9% stake
BioRestorative Therapies (BRTX) shareholder Kaos Capital, a Miami-based hedge fund focused on activist investing, has acquired 4.9% of the issued and outstanding common stock of the company. This owne...
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)
Urgently seeks meeting with the BRTX Board to discuss opportunities to unlock value for all shareholders MIAMI, May 27, 2026 /PRNewswire/ - Kaos Capital Ltd. ("Kaos Capital" or "we"), a Miami-based he...
BioRestorative Therapies completes Phase 2 dosing of BRTX-100
BioRestorative Therapies (BRTX) announced that the last patient has been dosed in its fully enrolled Phase 2 clinical trial evaluating BRTX-100 for the treatment of chronic lumbar disc disease, comple...
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B meeti...
BioRestorative Therapies Quarterly report: Q1 2026
BioRestorative Therapies has published its Q1 2026 quarterly earnings report on May 14, 2026.
BioRestorative Therapies presents preclinical data on MSC exosome proteomics
BioRestorative Therapies (BRTX) announces the presentation of new preclinical data at the International Society for Cell & Gene Therapy 2026 Annual Meeting, which took place May 6-9 in Dublin, Ireland...
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals
Data demonstrate distinct functional signatures across MSC-derived extracellular vesicles supporting targeted regenerative and aesthetic applications
BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100
BioRestorative Therapies (BRTX) announced expanded blinded data from its fully enrolled Phase 2 clinical trial evaluating BRTX-100, the Company’s autologous hypoxic-cultured mesenchymal stem cell ther...
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
Oral presentation at ISCT 2026 included larger 52-week follow-up cohort, with 52% of evaluable patients achieving at least 50% improvement in both VAS pain and ODI function measures and no dose-limiti...
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
Data demonstrate progress in each of its MSC-derived programs MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BR...
BioRestorative Therapies Slides: Corporate presentation
BioRestorative Therapies has posted slides in relation to its latest quarterly earnings report, which was published on April 24, 2026.
BioRestorative Therapies announces partnership with David Goldberg, M.D.
BioRestorative Therapies (BRTX) announced a strategic partnership with David Goldberg, M.D., J.D. Through the agreement, the Company is seeking to accelerate both scientific validation and market adop...
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform
Collaboration establishes an independent clinical validation pathway, expands access to influential physician networks, and strengthens the foundation for possible broad commercial growth across profe...
BioRestorative Therapies Proxy statement: Proxy filing
BioRestorative Therapies filed a proxy statement on April 13, 2026, providing details for shareholder voting and corporate governance matters.
BioRestorative Therapies announces strategic collaboration with 203 Creates
BioRestorative Therapies (BRTX) announced a strategic collaboration with 203 Creates. The collaboration is designed to advance BioRestorative’s biocosmeceutical platform by establishing a differentiat...
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform
Partnership to drive brand architecture, go-to-market execution, and global launch of the Company's product portfolio bridging biotechnology and premium skincare
BioRestorative Therapies Proxy statement: Proxy filing
BioRestorative Therapies filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.
BioRestorative Therapies price target lowered to $15 from $18 at Roth Capital
Roth Capital analyst Jonathan Aschoff lowered the firm’s price target on BioRestorative Therapies (BRTX) to $15 from $18 and keeps a Buy rating on the shares. In the company’s updated…
BioRestorative Therapies reports blinded data from mesenchymal stem cells trial
BioRestorative Therapies (BRTX) announced blinded data from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease, with 50% or ...